Icotrokinra

Chemical formula: C₉₀H₁₂₀N₂₀O₂₂S₂  Molecular mass: 1,896.833 g/mol  PubChem compound: 162462321

Therapeutic indications

Icotrokinra is indicated for:

Moderate to severe plaque psoriasis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

ICOTYDE is indicated for the treatment of moderate to severe plaque psoriasis in adults, and adolescents 12 years of age and older and weighing at least 40 kg, who are candidates for systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Icotrokinra is contraindicated in the following cases:

Lactation

Lactation

Clinically important active infections

Infectious disease

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈